Gene · 7301
Papers2,825
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 2,825
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities. | Front Mol Biosci | 2023 | 36845555 | PubTator, text mining | PubMed |
| MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. | J Thorac Oncol | 2023 | 36842467 | PubTator, text mining | PubMed |
| Selective Targeting of Cancer-Related G-Quadruplex Structures by the Natural Compound Dicentrine. | Int J Mol Sci | 2023 | 36835480 | PubTator, text mining | PubMed |
| A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia. | Int J Mol Sci | 2023 | 36835239 | PubTator, text mining | PubMed |
| The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. | Int J Mol Sci | 2023 | 36834641 | PubTator, text mining | PubMed |
| Immune Recognition versus Immune Evasion Systems in Zika Virus Infection. | Biomedicines | 2023 | 36831177 | PubTator, text mining | PubMed |
| Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II. | Cureus | 2023 | 36824546 | PubTator, text mining | PubMed |
| Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. | Cell Mol Immunol | 2023 | 36823234 | PubTator, text mining | PubMed |
| Modified prolonged exposure therapy as Early Intervention after Rape (The EIR-study): study protocol for a multicenter randomized add-on superiority trial. | Trials | 2023 | 36810120 | PubTator, text mining | PubMed |
| SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. | J Immunother Cancer | 2023 | 36808075 | PubTator, text mining | PubMed |
| APOE4 drives transcriptional heterogeneity and maladaptive immunometabolic responses of astrocytes. | bioRxiv | 2023 | 36798317 | PubTator, text mining | PubMed |
| Antibodies to repeat-containing antigens in Plasmodium falciparum are exposure-dependent and short-lived in children in natural malaria infections. | Elife | 2023 | 36790168 | PubTator, text mining | PubMed |
| Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare Partners. | Mod Pathol | 2023 | 36788092 | PubTator, text mining | PubMed |
| BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma. | Front Oncol | 2023 | 36776328 | PubTator, text mining | PubMed |
| Follicular Thyroid Adenoma and Follicular Thyroid Carcinoma-A Common or Distinct Background? Loss of Heterozygosity in Comprehensive Microarray Study. | Cancers (Basel) | 2023 | 36765597 | PubTator, text mining | PubMed |
| Microglial Activation in Metal Neurotoxicity: Impact in Neurodegenerative Diseases. | Biomed Res Int | 2023 | 36760476 | PubTator, text mining | PubMed |
| Chicken-derived MERTK protein inhibits Newcastle disease virus replication by increasing STAT1 phosphorylation in DF-1 cells. | Virus Res | 2023 | 36754292 | PubTator, text mining | PubMed |
| The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors. | Cell Death Discov | 2023 | 36739272 | PubTator, text mining | PubMed |
| An insight into the TAM system in Alzheimer's disease. | Int Immunopharmacol | 2023 | 36738678 | PubTator, text mining | PubMed |
| Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. | Mol Cell | 2023 | 36736316 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7301/papers?page=23